This is a preview of subscription content, log in via an institution to check access.
Notes
progression-free survival
Reference
Refaat T, et al. Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. American Journal of Clinical Oncology 37: No. 5, Oct 2014. Available from: URL: http://dx.doi.org/10.1097/COC.0b013e31827e4e9a
Rights and permissions
About this article
Cite this article
Bevacizumab in HER2-negative MBC: PFS benefit at high cost. PharmacoEcon Outcomes News 720, 13 (2015). https://doi.org/10.1007/s40274-015-1852-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-1852-0